Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481674 · ClinicalTrials.gov registry record · Phase 2
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
A Phase 2 study, sponsored by Vaccinex.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
NCT02481674 is a Phase 2 study that has completed, run by Vaccinex. The registered enrollment target is 301 participants.
The verdict
NCT02481674, a Phase 2 study, has completed, sponsored by Vaccinex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
Interventions
- DRUG Placebo
- DRUG VX15/2503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2015-07 |
| Est. Completion | 2020-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02481674
The ClinicalTrials.gov registry entry for NCT02481674 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaccinex, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02481674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02481674 about?
NCT02481674 is a clinical study titled "A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi". The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
What is the current status of trial NCT02481674?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2015-07. Estimated completion is 2020-08.
What interventions are being tested in trial NCT02481674?
The interventions under investigation include: Placebo (DRUG), VX15/2503 (DRUG).
Who is sponsoring clinical trial NCT02481674?
This trial is sponsored by Vaccinex, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.